Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

FDA grants fast track designation to promising metastatic breast cancer treatment

July 6, 2016

By Life Science Daily

On the merit of promising results in earlier combination studies, Cascadian Therapeutics’ HER2+ metastatic breast cancer study has recently been given fast track designation by the U.S. Food and Drug Administration (FDA). The program, called HER2CLIMB, will move into phase two shortly, evaluating the effectiveness of a highly selective small molecule inhibitor of HER2 called ONT-380.

Expert Perspectives in the Latest Advancments in Breast Cancer

June 29, 2016

By OncLive

Video from leading researchers exchange discussion on the management of advanced breast cancer. Covers the data that has come out over the last few months, including information from ASCO 2016, and adding important perspective on how this information can be used in clinical practice.

Sloan Kettering’s Quest to Prove Exercise Can Inhibit Cancer

March 1, 2016

By Wall Street Journal

Trying ‘exercise oncology’ to stop or delay the spread of a malignant tumor; a trial for women with stage 4 breast cancer

Key Studies Help Chart Course in HER2-Positive Breast Cancer

February 28, 2016

By OncLive

Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease.

Predictive Proteins: Elevated Levels Trigger Metastatic Progression of Cancer Cells

February 27, 2016

By UCSanDiego Health

New biomarker may offer more precise and accurate prognoses of disease.

The Breast Cancer Research Foundation Launches First-of-Its-Kind Breast Cancer Clinical Research Funding Model

February 24, 2016

By PR Newswire

The Breast Cancer Research Foundation (BCRF) announced the expansion of its research program with a new collaborative breast cancer funding model—the BCRF Investigator-Initiated Drug Research Program—that will help broaden and accelerate clinical research on treatment strategies for people with breast cancer.

fizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer First-in-class Therap

February 21, 2016

By Pfizer Press Release

Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer

    First-in-class Therapy Now Approved for Use in a Broader Range of Women
    New Indication Supported by Results of Phase 3 PALOMA-3 Trial of IBRANCE in Combination with Fulvestrant

Friday, February 19, 2016 - 4:35pm

“Today's news gives more women with metastatic breast cancer the opportunity to benefit from this first-in-class medicine”

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.1 Pfizer’s supplemental New Drug Application (sNDA) for IBRANCE was reviewed and approved under the FDA’s Breakthrough Therapy designation and Priority Review programs based on results from the Phase 3 PALOMA-3 trial in pre-, peri- and post-menopausal women with HR+, HER2- metastatic breast cancer whose disease progressed on or after prior endocrine therapy in the adjuvant or metastatic setting.1

Breast Cancer Research Sheds New Light on HR-Positive Disease

February 17, 2016

By Oncology Live

In the area of hormone receptor (HR)–positive breast cancer, study findings reported in recent months in journals and at the 2015 San Antonio Breast Cancer Symposium (SABCS) have helped refine the optimal use of endocrine therapies including strategies for combining these agents with targeted drugs.

Red Blood Cell Transfusion Preferred Over Epoetin Alfa for Treatment of Anemia in Breast Cancer

February 11, 2016

By Cancer Therapy Advisor

Red blood cell transfusion and not epoetin alfa (EPO) should be the preferred approach in treating patients with metastatic breast cancer and anemia, according to a study published in the Journal of Clinical Oncology.

Topics ASCO 2015 Breast Cancer Targets

February 6, 2016

By Oncotherapy Network

Data analysis from several cancer research centers suggests new opportunities in breast cancer treatment and pathways.

 1 2 3 >  Last ›